SCHEMBL30325880

SCHEMBL30325880

C=CC(=O)Nc1ccc(-c2c(-c3ccc(Oc4ncc(Cl)c(C)n4)cc3)c3c(N)ncc(C#N)c3n2C)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BTK Q06187 9/20 0.36
FGFR1 P11362 2/20 0.35
FGFR2 P21802 2/20 0.35
FGFR4 P22455 2/20 0.35
FGFR3 P22607 2/20 0.35
CCNK O75909 2/20 0.35
CDK12 Q9NYV4 2/20 0.35
MALT1 Q9UDY8 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
EGFR P00533 7/20 0.34
KCNH2 Q12809 1/20 0.34
MAP2K7 O14733 1/20 0.33
BLK P51451 2/20 0.33
FLT3 P36888 2/20 0.33
MAPK3 P27361 1/20 0.33
ERBB2 P04626 1/20 0.33
RET P07949 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30326074 0.93 BTK (0.36) BTKMALT1EGFRKCNH2BLK
SCHEMBL30325658 0.92 BTK (0.35) BTKMALT1EGFRKCNH2BLK
SCHEMBL31214001 0.92 FGFR4 (0.40) BTKFGFR1FGFR2FGFR4FGFR3
SCHEMBL31213869 0.92 FGFR1 (0.39) BTKFGFR1FGFR2FGFR4FGFR3
SCHEMBL30325747 0.91 FGFR4 (0.39) BTKFGFR1FGFR2FGFR4FGFR3
SCHEMBL29265747 0.91 FGFR4 (0.39) BTKFGFR1FGFR2FGFR4FGFR3
SCHEMBL30325852 0.91 BTK (0.35) BTKFGFR1FGFR2FGFR4FGFR3
SCHEMBL31213996 0.90 FGFR1 (0.35) BTKFGFR1FGFR2FGFR4FGFR3
SCHEMBL31213884 0.90 BTK (0.36) BTKFGFR1FGFR2FGFR4FGFR3
SCHEMBL30325779 0.90 MAP2K7 (0.37) BTKFGFR1FGFR2FGFR4FGFR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240383905-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF 3H PHARMACEUTICALS CO., LTD. (CN) 2024-11-21 US claimed
EP-4405358-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF 3H Pharmaceuticals Co., Ltd. (CN) 2024-07-31 EP claimed
WO-2023046117-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF 3H PHARMACEUTICALS CO., LTD. (CN) 2023-03-30 WO claimed
US-20240383905-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF 3H PHARMACEUTICALS CO., LTD. (CN) 2024-11-21 US disclosed
EP-4405358-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF 3H Pharmaceuticals Co., Ltd. (CN) 2024-07-31 EP disclosed
WO-2023046117-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF 3H PHARMACEUTICALS CO., LTD. (CN) 2023-03-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240383905-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF FGFR1, FGFR3, FGFR4 BTK 168/4885FGFR1 1/4885FGFR2 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.